scholarly journals Diabetic Nephropathy: Role of Aldosterone and Benefits of Therapy with Aldosterone Receptor Blocker

10.5772/34854 ◽  
2012 ◽  
Author(s):  
Jayson Yap ◽  
Mohammad G.
Keyword(s):  
Diabetic Nephropathy ◽  
Receptor Blocker ◽  
Aldosterone Receptor

scholarly journals The role of aldosterone receptor blocker therapy in hypertension and heart failure

2015 ◽  
Vol 8 ◽  
pp. 34-37 ◽  
Author(s):  
Giuseppina Santese ◽  
Cosimo Stefanio ◽  
Gianluca Belletti ◽  
Maria Boiani ◽  
Antonietta Schipani ◽  
...  
Keyword(s):  
Heart Failure ◽  
Receptor Blocker ◽  
Blocker Therapy ◽  
Aldosterone Receptor

scholarly journals Protective Effect of Angiotensin II Type 1-Receptor-Blocker on Diabetic Nephropathy in Rats: Role of Nephrin

2020 ◽  
Vol 88 (12) ◽  
pp. 2081-2089
Author(s):  
ALAA I. ALI, M.D.; DOAA A. ABDEL MOETY, M.D. ◽  
EBTESAM M. IBRAHIM, M.D.; MAHMOUD M.A. ABULMEATY, M.D.
Keyword(s):  
Diabetic Nephropathy ◽  
Angiotensin Ii ◽  
Protective Effect ◽  
Receptor Blocker

scholarly journals Role of endocannabinoid CB1 receptors in Streptozotocin-induced uninephrectomised Wistar rats in diabetic nephropathy

2021 ◽  
Vol 10 (1) ◽  
Author(s):  
Jayarami Reddy Medapati ◽  
Deepthi Rapaka ◽  
Veera Raghavulu Bitra ◽  
Santhosh Kumar Ranajit ◽  
Girija Sankar Guntuku ◽  
...  
Keyword(s):  
Diabetic Nephropathy ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Morphological Changes ◽  
Serum Levels ◽  
Cb1 Receptors ◽  
Protective Effects ◽  
Renal Hypertrophy ◽  
Necrosis Factor Alpha

Abstract Background The endocannabinoid CB1 receptor is known to have protective effects in kidney disease. The aim of the present study is to evaluate the potential agonistic and antagonistic actions and to determine the renoprotective potential of CB1 receptors in diabetic nephropathy. The present work investigates the possible role of CB1 receptors in the pathogenesis of diabetes-induced nephropathy. Streptozotocin (STZ) (55 mg/kg, i.p., once) is administered to uninephrectomised rats for induction of experimental diabetes mellitus. The CB1 agonist (oleamide) and CB1 antagonist (AM6545) treatment were initiated in diabetic rats after 1 week of STZ administration and were given for 24 weeks. Results The progress in diabetic nephropathy is estimated biochemically by measuring serum creatinine (1.28±0.03) (p < 0.005), blood urea nitrogen (67.6± 2.10) (p < 0.001), urinary microprotein (74.62± 3.47) (p < 0.005) and urinary albuminuria (28.31±1.17) (p < 0.0001). Renal inflammation was assessed by estimating serum levels of tumor necrosis factor alpha (75.69±1.51) (p < 0.001) and transforming growth factor beta (8.73±0.31) (p < 0.001). Renal morphological changes were assessed by estimating renal hypertrophy (7.38± 0.26) (p < 0.005) and renal collagen content (10.42± 0.48) (p < 0.001). Conclusions From the above findings, it can be said that diabetes-induced nephropathy may be associated with overexpression of CB1 receptors and blockade of CB1 receptors might be beneficial in ameliorating the diabetes-induced nephropathy. Graphical abstract

scholarly journals The Role of Apelin on the Alleviative Effect of Angiotensin Receptor Blocker in Unilateral Ureteral Obstruction-Induced Renal Fibrosis

Nephron Extra ◽  
2012 ◽  
Vol 2 (1) ◽  
pp. 39-47 ◽  
Author(s):  
Masashi Nishida ◽  
Yasuko Okumura ◽  
Tatsujiro Oka ◽  
Kentaro Toiyama ◽  
Seiichiro Ozawa ◽  
...  
Keyword(s):  
Ureteral Obstruction ◽  
Renal Fibrosis ◽  
Angiotensin Receptor Blocker ◽  
Unilateral Ureteral Obstruction ◽  
Receptor Blocker ◽  
Angiotensin Receptor

scholarly journals Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy

2000 ◽  
Vol 57 ◽  
pp. S32-S37 ◽  
Author(s):  
Hendrik Bos ◽  
Steen Andersen ◽  
Peter Rossing ◽  
Dick de Zeeuw ◽  
Hans-Henrik Parving ◽  
...  
Keyword(s):  
Diabetic Nephropathy ◽  
Therapy Resistance ◽  
Patient Factors
Sign in / Sign up

Export Citation Format

Share Document